HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Peter Lamm Gerd Juchem Bruno Reichart Permission Requests Google Scholar Articles by Lamm, P. Articles by Reichart, B. PubMed Articles by Lamm, P. Articles by Reichart, B. Related Collections Cardiac - pharmacology Cardiac - other Coronary disease Myocardial infarction

Letters to the Editor

Reply to McGoldrick and White

Department of Cardiac Surgery, Ludwig-Maximilians University of Munich, Germany

Received 6 February 2008; accepted 7 February 2008.

^_* Corresponding author. Address: Department of Cardiac Surgery, Herzklinik der Universität München, Wolkerweg 16, 81375 München, Germany. Tel.: +49 89 7097 1844; fax: +49 89 7097 1848. (Email: lamm@lrz.uni-muenchen.de).

Key Words: Coronary

The first 20% of the full text of this article appears below.

We thank the Editor for giving us the opportunity to reply to McGoldrick and White's letter to the Editor [1].

There is indeed a basis supporting a causal relationship between sealant use and graft thrombosis.

Free thrombin is undoubtedly deleterious when reaching the circulation system.

In vitro tests done to shed light on the thrombin release as a parameter of non-reacting components and its dependence on the application technique show that there is a release of thrombin into the supernatant for at least 120 h after application even when Duploject application was used [2]. Some studies . . . [Full Text of this Article]